GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Construction In Progress

Advagene Biopharma Co (ROCO:6709) Construction In Progress : NT$0.00 Mil (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Construction In Progress?


Advagene Biopharma Co Construction In Progress Historical Data

The historical data trend for Advagene Biopharma Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Construction In Progress Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Get a 7-Day Free Trial - - - - -

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Advagene Biopharma Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Advagene Biopharma Co (ROCO:6709) Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co (ROCO:6709) Headlines

No Headlines